Quinn Opportunity Partners LLC Purchases Shares of 30,000 Biohaven Ltd. $BHVN

Quinn Opportunity Partners LLC acquired a new position in shares of Biohaven Ltd. (NYSE:BHVN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 30,000 shares of the company’s stock, valued at approximately $423,000.

A number of other large investors have also modified their holdings of BHVN. PNC Financial Services Group Inc. boosted its stake in Biohaven by 53.7% during the first quarter. PNC Financial Services Group Inc. now owns 1,783 shares of the company’s stock worth $43,000 after buying an additional 623 shares in the last quarter. RWA Wealth Partners LLC increased its stake in Biohaven by 7.0% in the first quarter. RWA Wealth Partners LLC now owns 12,622 shares of the company’s stock valued at $303,000 after acquiring an additional 822 shares during the period. SVB Wealth LLC bought a new position in Biohaven during the first quarter worth about $25,000. Advisors Asset Management Inc. boosted its holdings in Biohaven by 5.7% during the first quarter. Advisors Asset Management Inc. now owns 23,905 shares of the company’s stock valued at $575,000 after purchasing an additional 1,290 shares in the last quarter. Finally, E Fund Management Co. Ltd. grew its stake in shares of Biohaven by 16.4% in the 1st quarter. E Fund Management Co. Ltd. now owns 11,185 shares of the company’s stock valued at $269,000 after purchasing an additional 1,572 shares during the period. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Biohaven Stock Down 6.9%

Shares of BHVN opened at $7.94 on Thursday. The firm has a market capitalization of $840.10 million, a price-to-earnings ratio of -1.04 and a beta of 1.10. Biohaven Ltd. has a 52 week low of $7.48 and a 52 week high of $51.81. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.82 and a current ratio of 2.86. The business’s fifty day moving average price is $14.67 and its two-hundred day moving average price is $15.37.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, November 10th. The company reported ($1.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.91) by $0.27. On average, analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on BHVN shares. BTIG Research cut their target price on Biohaven from $33.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. TD Cowen dropped their price objective on Biohaven from $50.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Raymond James Financial reissued a “strong-buy” rating on shares of Biohaven in a report on Wednesday, November 5th. Leerink Partners lowered their target price on shares of Biohaven from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Tuesday, August 12th. Finally, Citigroup began coverage on shares of Biohaven in a research report on Wednesday, September 17th. They set a “buy” rating and a $28.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $34.21.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.